Clinical trial · Observational
NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers
NCT00318266CI-TRIAL-00029270completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
It is hypothesized that the NMP22(Nuclear Matrix Protein) Bladder Check ® Test will demonstrate improved sensitivity over that of standard urine cytology for patients with superficial transitional cell carcinoma at high risk of recurrence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nuclear Matrix Protein 22 Urine sample kit | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients with suerficial transitional cell carcinoma
- interventionNames
- Device: Nuclear Matrix Protein 22 Urine sample kit
Primary outcomes (0)
[]Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * · History of pTis, pT1, large (\>2cm) pTa or multiple pTa bladder cancer tumours. Written Informed Consent prior to any study-related procedures. Exclusion Criteria: * History of bladder cancer tumours other than those listed in inclusion
References
Publications (0)
Data not yet available
No reference posted for this study.